Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

[EX Q]: Most people know roughly what a bottle of vitamin D supplements might cost them, so the lack of information on cost is not a significant gap. We appreciate that the story provided data showing the large and growing amount our society is spending on vitamin D supplements ($430 million in 2009), with apparently little health benefit to show for it. The story was mostly concerned with discussing the lack of benefit from taking extra vitamin D and calcium. And in this area it excels. While the story does lack precision when it suggests that adolescent girls should be getting more calcium (it never specifies how much they are getting now, how much more they’d need to meet the recommendations, or what benefits they might expect from this increased intake), it would be difficult for a journalist to come up with any sort of quantifiable benefit or harm estimate from the IOM report. The story captured the overall gist of the problem, which is that the evidence base is complex and still inadequate. The story notes that, contrary to the claims of many advocates for increased supplemental vitamin D, there is evidence that high levels of vitamin D may have adverse effects, such as increased risk for fractures and an increase in the overall death rate. The story also explained that too much calcium has been linked to increased risk of kidney stones and, more tentatively, heart disease. The story did a good job of describing how the expert committee conducted its review and what evidence they found. Importantly, it noted that  claims of benefit from extra vitamin D are based on observational studies that most scientists agree “cannot determine cause and effect.” We also like that the story solicited opinions from a variety of experts with no obvious stake in the controversy. This produced a number of quotes that emphasized the need for restraint when interpreting the research on vitamin D. Examples: “I think this report will make people more cautious” and “The onus is on the people who propose extra calcium and vitamin D to show it is safe before they push it on people.” Although we agree with the story’s skeptical overall message, we think it may have slammed the door just a bit too hard on the possibility of benefit from supplemental vitamin D. While claims of benefit may not be supported by the currently available evidence, they have not been conclusively disproved in randomized controlled studies, either. In fact, research is now underway to determine whether the benefits found in observational studies of vitamin D can be replicated in more rigorously designed trials. The story probably should have mentioned this research, and left the door to potential benefits open just a crack. No disease-mongering here. The diversity of independent voices included in this story is a real strength. Although it solicits the obligatory comment from a supplement industry spokesman, it didn’t go out of its way to find any of the more widely known vitamin D experts, some of whom have been issuing recommendations that are untenable based on current evidence. The enthusiasm of some of these researchers might be explained by their significant career and financial interests in promoting vitamin D. Not applicable for this story. The approaches discussed are not new, and there’s not really any alternative to getting adequate amounts of these essential nutrients. The availability of vitamin D from diet, sunlight and supplements is clear from the story. The novelty of vitamin D and calcium is not really in question, so we’ll call this not applicable. This story was not based on a news release.
[EX A]: Report Questions Need for 2 Diet Supplements

[EX Q]: Most cases are reported in the northern and eastern panhandles probably because of their proximity to the high-incidence states of Maryland, Pennsylvania, and Virginia, the Department of Health and Human Resources said. In an advisory Monday to health care providers, Health Commissioner Dr. Rahul Gupta wrote that the increase could be from increased reporting or from more ticks infected with the bacteria. Most cases appear between May and September, but ticks have become more active in winter months, he said. According to the department, 580 cases have been reported so far this year, up from 97 statewide in 2012. “Based on the change, West Virginia is considered a high incidence Lyme disease state,” Gupta wrote. Patients treated early with antibiotics usually recover quickly. He recommended a two-step blood test to confirm evidence of antibodies against the Lyme disease bacteria. Symptoms often include a circular rash around a tick bite and fever, headaches and fatigue, according to the U.S. Centers for Disease Control. If left untreated, the infection can spread to joints, the heart and the nervous system. The CDC says there were more than 36,000 probable cases in the U.S. last year, with 26,203 confirmed.
[EX A]: West Virginia reports increasing Lyme disease cases.

[EX Q]: "The story mentions that 30 capsules of OSR#1 cost $60. It would have been nice had the story also included information about the amount of active ingredient per capsule and the manufacturer’s recommended dosage. This would have allowed readers to make a better calculation as to the financial impact of treatment. This is critical information considering these costs will be borne out of pocket by anyone using OSR #1. The story juxtaposes a light-hearted ""success story"" with information about the industrial uses of OSR #1 for removing toxic heavy metals from contaminated soil. This is a clever way of way of emphasizing that the use of this product is based entirely on anecdote. The story clearly states that there is no credible evidence supporting the efficacy of the product. The harms of this product are impossible to quantify, given that it doesn’t seem to have been studied in humans or in animals. The story notes that other chelating drugs carry ""significant risks"" and ""can strip the body of metals necessary for health."" It would have been nice to see more specifics about what chelators can do, but the story satisfies the critierion. The story states that medical searches turned up no papers about OSR#1, and that the company which makes the product provided no published studies about its use. The story rightly suggests that this total lack of evidence should be deeply troubling. The story doesn’t exaggerate the prevalence or severity of autism, or of the potentially toxic compounds sometimes used to treat it. The story quotes multiple experts on pharmacology and an FDA spokesperson. It also quotes from an interview with Boyd Haley, president of the company which makes OSR #1. It attempted to get a reaction from Kim Stagliano, an OSR #1 proponent, but this effort was not successful. While the story mentions that there other are chelation drugs out there, it could have mentioned that there are educational strategies which can be helpful for children with autism and which have better evidence to support their use. The story states that OSR#1 is, according to the manufacturer’s website, available only through dentists’ or doctors’ offices. It notes, however, that the Tribune was able to buy 30 capsules of the product directly from a compounding pharmacy listed on the site. We are impressed that the Tribune went to these lengths to establish the product’s availability. The story provides a fairly detailed pedigree for OSR #1 and discusses its similarity to other chelation therapies used in the treatment of autism. It also gives credit to blogger Kathleen Seidel for being the first to raise concerns about OSR #1 in her blog, Neurodiversity.com The story is well sourced and is not based on a press release."
[EX A]:
Industrial chemical OSR#1 used as autism treatment